Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash & Equivalents for 7 consecutive years, with $294.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 4.6% to $294.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $294.9 million, a 4.6% increase, with the full-year FY2025 number at $294.9 million, up 4.6% from a year prior.
  • Cash & Equivalents was $294.9 million for Q4 2025 at Beam Therapeutics, up from $268.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $612.0 million in Q3 2021 to a low of $97.2 million in Q1 2021.
  • A 5-year average of $298.9 million and a median of $275.0 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 343.81% in 2021, then tumbled 74.43% in 2022.
  • Beam Therapeutics' Cash & Equivalents stood at $560.0 million in 2021, then plummeted by 58.43% to $232.8 million in 2022, then skyrocketed by 87.27% to $435.9 million in 2023, then tumbled by 35.31% to $282.0 million in 2024, then rose by 4.6% to $294.9 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Cash & Equivalents are $294.9 million (Q4 2025), $268.0 million (Q3 2025), and $282.1 million (Q2 2025).